Table 2.

Part of GFs employed in clinical trial or application.

Name	Type of diseases	Dosage	Outcomes	Ref.
NGF	Chronic ulcerations	50 μL/day (200 μg/mL) for 4–6 weeks	• Accelerating wound healing of the chronic cutaneous ulcer	[154]
			• Inducing angiogenesis
	Diabetic neuropathy	0.1 μg/kg rhNGF subcutaneously three times a week for 6 months	• protecting peripheral nervous system neurons and normalizing their activity • Causing acute pain reaction	[155]
FGF1	Spinal cord injury	combination FGF1 and fibrin glue (2 mL) at 3 and 6 months postsurgery via lumbar puncture.	• Improving ASIA motor and sensory scale scores • Increasing the intrinsic activity of neurons	[156]
FGF2	Type 2 diabetes mellitus	0.5 μg/kg per day FGF1 for 16 weeks	• Improving glucose sensing and uptake • Enhancing insulin sensitivity	[157]
	Acute stroke	Patients were intravenously administered FGF2 ranging from 3 to 150 μg/kg for 24 h	• Significant reducing intracerebral hemorrhage • A mild advantage on decreasing mortality rates	[158]